KRAS G12C is rare in PDAC (~1-2%, vs ~30% G12D and ~25% G12V). Sotorasib (CodeBreaK 100 P...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-G12C-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-KRAS-G12C |
|---|---|
| Variant | G12C |
| Disease | DIS-PDAC |
| ESCAT tier | IIB |
| Recommended combinations | sotorasib monotherapy, adagrasib monotherapy |
| Evidence summary | KRAS G12C is rare in PDAC (~1-2%, vs ~30% G12D and ~25% G12V). Sotorasib (CodeBreaK 100 PDAC cohort, Strickler et al. NEJM 2023) ORR 21%, PFS 4 mo in pretreated G12C PDAC. Adagrasib (KRYSTAL-1 GI cohort) ORR 33%. NCCN recommends in 2L+. |
Notes
ESCAT IIB. OncoKB Level 3A. Reflex KRAS sequencing in metastatic PDAC because G12C and G12D are now actionable.
Used By
No reverse references found in the YAML corpus.